Literature DB >> 18291553

miR-122, a paradigm for the role of microRNAs in the liver.

Muriel Girard1, Emmanuel Jacquemin, Arnold Munnich, Stanislas Lyonnet, Alexandra Henrion-Caude.   

Abstract

Recent studies have uncovered profound and unexpected roles for a family of tiny regulatory RNAs, known as microRNAs (miRNAs), in the control of diverse aspects of hepatic function and dysfunction, including hepatocyte growth, stress response, metabolism, viral infection and proliferation, gene expression, and maintenance of hepatic phenotype. In liver cancer, misexpression of specific miRNAs suggests diagnostic and prognostic significance. Here, we review the biology of the most abundant miRNA in human liver, miR-122, and consider the diversity of its roles in the liver. We provide a compilation of all miRNAs expressed in the liver, and consider some possible therapeutic opportunities for exploiting miRNAs in the different settings of liver diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18291553     DOI: 10.1016/j.jhep.2008.01.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  152 in total

1.  Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma.

Authors:  Zehra Oksuz; Mehmet Sami Serin; Engin Kaplan; Aylin Dogen; Seda Tezcan; Gonul Aslan; Gurol Emekdas; Orhan Sezgin; Engin Altintas; Eyup Naci Tiftik
Journal:  Mol Biol Rep       Date:  2014-11-13       Impact factor: 2.316

2.  Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells.

Authors:  Xinping Fu; Armando Rivera; Lihua Tao; Bart De Geest; Xiaoliu Zhang
Journal:  Mol Ther       Date:  2011-12-06       Impact factor: 11.454

3.  Tiling genomes of pathogenic viruses identifies potent antiviral shRNAs and reveals a role for secondary structure in shRNA efficacy.

Authors:  Xu Tan; Zhi John Lu; Geng Gao; Qikai Xu; Long Hu; Christof Fellmann; Mamie Z Li; Hongjing Qu; Scott W Lowe; Gregory J Hannon; Stephen J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

4.  Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs.

Authors:  Luisa Novellino; Riccardo L Rossi; Ferruccio Bonino; Daniela Cavallone; Sergio Abrignani; Massimiliano Pagani; Maurizia R Brunetto
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

5.  Increased hepatic expression of miRNA-122 in patients infected with HCV genotype 3.

Authors:  Ketti G Oliveira; Fernanda M Malta; Ana C S S Nastri; Azzo Widman; Paola L Faria; Rúbia A F Santana; Venâncio A F Alves; Flair J Carrilho; João R R Pinho
Journal:  Med Microbiol Immunol       Date:  2015-08-14       Impact factor: 3.402

Review 6.  MicroRNAs and liver disease.

Authors:  Thomas A Kerr; Kevin M Korenblat; Nicholas O Davidson
Journal:  Transl Res       Date:  2011-02-02       Impact factor: 7.012

Review 7.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

8.  Positive Regulation of Hepatitis E Virus Replication by MicroRNA-122.

Authors:  Bangari Haldipur; Prudhvi Lal Bhukya; Vidya Arankalle; Kavita Lole
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

9.  Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion.

Authors:  Changfei Li; Yanzhong Wang; Saifeng Wang; Bo Wu; Junli Hao; Hongxia Fan; Ying Ju; Yuping Ding; Lizhao Chen; Xiaoyu Chu; Wenjun Liu; Xin Ye; Songdong Meng
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

10.  Interplay between microRNA-17-5p, insulin-like growth factor-II through binding protein-3 in hepatocellular carcinoma.

Authors:  Danira Ashraf Habashy; Hend Mohamed El Tayebi; Injie Omar Fawzy; Karim Adel Hosny; Gamal Esmat; Ahmed Ihab Abdelaziz
Journal:  World J Hepatol       Date:  2016-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.